FoRx Therapeutics is an incorporated privately held drug discovery company based in Basel, Switzerland.
The company focuses on the discovery and development of small molecule inhibitors against key proteins involved in the response to DNA Replication Stress, which constitutes an innovative approach in the development of targeted anti-cancer drugs. FoRx Therapeutics is backed by a syndicate of investors that include EQT Life Sciences, Novartis Venture Fund, Pfizer Ventures, M Ventures and Omega Funds.
Recent Milestones: - Lead program (PARG): Demonstration of potent single-agent activity in vivo and clear differentiation from competitor - Second program: Generation of compounds with nanomolar activity
Upcoming Milestones: - Lead program (PARG): Development Candidate declaration and move forward to IND - Second program: Lead compound with demonstrated single-agent activity in vivo Products: N/A
Investors: • EQT Life Sciences • Novartis Venture Fund • M Ventures • Pfizer Ventures • Omega Funds